08:00 , Dec 20, 2012 |  BC Innovations  |  Targets & Mechanisms

Targeting interleukins in Alzheimer's disease

Researchers at Charité-University Hospital Berlin and the University of Zurich have data showing that p40, a protein subunit shared by IL-12 and IL-23 , could be a new therapeutic target in Alzheimer's disease. 1 The...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Adenosine A2 receptor (ADORA2) In vitro and mouse studies suggest ADORA2 agonist-treated dendritic cells (DCs) could help treat acute kidney injury. Mice...
07:00 , Jun 14, 2012 |  BC Innovations  |  Targets & Mechanisms

Beta testing adenosine receptor agonists

Researchers at the University of California, San Francisco have used a zebrafish screen to identify an adenosine receptor agonist that improved both b cell regeneration and glucose control in diabetic mice. 1 The discovery could...
07:00 , Oct 6, 2011 |  BC Innovations  |  Cover Story

Opening the brain

A Cornell University team has proposed a new strategy for delivering large-molecule therapeutics into the CNS: agonizing adenosine receptors in the brain's vasculature to loosen up the blood brain barrier. 1 Private equity company KensaGroup...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Clinical News

OPA-6566: Phase I/II started

Acucela Inc. (Seattle, Wash.) began a single-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial in about 120 patients comparing OPA-6566 vs. daily latanoprost. Patients will receive OPA-6566 daily for 2 weeks and twice daily for an...
08:00 , Jan 20, 2011 |  BC Innovations  |  Cover Story

Two edges of sickle cell disease

A U.S.-China team has shown that inhibiting signaling between adenosine and the adenosine A 2B receptor in blood could prevent vaso-occlusion and consequent organ damage in sickle cell disease. 1 The researchers already are in...
07:00 , Oct 15, 2009 |  BC Innovations  |  Cover Story

A gut feeling for CD39

Researchers have reported that enhancing CD39 activity in the gut could trigger a T reg -mediated immunosuppressive response to help treat inflammatory bowel disease. 1 The researchers are now developing a soluble form of CD39...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

Acadesine: Phase III started

Schering-Plough began the double-blind, placebo-controlled, international Phase III RED-CABG trial to evaluate 42 mg/kg IV acadesine given over 7 hours in 7,500 patients. Administration will begin within 30 minutes of the induction of anesthesia and...
08:00 , Mar 5, 2009 |  BC Innovations  |  Targets & Mechanisms

Adenosine dreams

Adenosine's role in stimulating sleep has been known since the 1980s, but efforts to target the molecule and its receptor have been stymied by uncertainty about where the adenosine pathway acts in the brain and...
07:00 , Oct 23, 2008 |  BC Innovations  |  Targets & Mechanisms

PAP Over Poppies

A team of researchers from Finland and the U.S. has shown that prostatic acid phosphatase-a protein...